Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.antiviral.2019.104637
Title: Antiviral activity of the FDA-approved drug candesartan cilexetil against Zika virus infection
Authors: Loe, MWC 
Lee, RCH
Chu, JJH 
Keywords: Antiviral
FDA-approved compounds
High-throughput screening
Zika
Issue Date: 1-Dec-2019
Publisher: Elsevier BV
Citation: Loe, MWC, Lee, RCH, Chu, JJH (2019-12-01). Antiviral activity of the FDA-approved drug candesartan cilexetil against Zika virus infection. Antiviral Research 172 : 104637-. ScholarBank@NUS Repository. https://doi.org/10.1016/j.antiviral.2019.104637
Abstract: © 2019 Elsevier B.V. Zika virus (ZIKV) is a mosquito-borne virus that has risen to prominence as a significant threat to public health in the recent decade. Since its re-emergence in 2007, ZIKV has spread at an alarming rate and has since become endemic to multiple regions around the world. Infections are primarily asymptomatic, however the virus has become associated with the development of severe neurological complications such as Guillain–Barré syndrome (GBS) and congenital microcephaly. At present, there are currently no approved antivirals for ZIKV infections. In this study, we utilised a phenotype-based screening platform to perform a high-throughput screen on a 1172-compound US FDA-approved drug library to identify potential novel inhibitors against ZIKV. Candesartan cilexetil, an angiotensin II receptor inhibitor, displayed potent inhibition effects against ZIKV and subsequent downstream time-course studies revealed that it targets a post-entry stage(s) of the ZIKV replication cycle. Moreover, candesartan cilexetil also inhibited viral RNA production and viral protein synthesis. Candesartan cilexetil also exhibited antiviral effects against Dengue virus serotype-2 (DENV2), Kunjin virus (KUNV) and Chikungunya virus (CHIKV), indicating that its antiviral properties may not be restricted to ZIKV. Our study has demonstrated for the first time the potential application of candesartan cilexetil as an antiviral.
Source Title: Antiviral Research
URI: https://scholarbank.nus.edu.sg/handle/10635/173210
ISSN: 01663542
18729096
DOI: 10.1016/j.antiviral.2019.104637
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
6.pdfAccepted version2.94 MBAdobe PDF

OPEN

Post-printView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.